Emerging off-label uses for recombinant activated factor VII: Grading the evidence

T. Miko Enomoto, Per Thorborg

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Recombinant factor VIIa holds a great deal of promise as a hemostatic agent in many clinical settings; however, more large, randomized, controlled trials are needed to evaluate both the safety and efficacy of this apparently effective hemostatic agent, particularly in view of its cost. Cost-effectiveness studies are only in the planning stage for rFVIIa as of yet. To become cost-effective, dosing of rFVIIa should avoid costly returns in the operating room, shorten stays in the ICU, and prevent the need to give an additional 10 units of blood.

Original languageEnglish (US)
Pages (from-to)611-632
Number of pages22
JournalCritical Care Clinics
Volume21
Issue number3 SPEC. ISS.
DOIs
StatePublished - Jul 2005

Fingerprint

Off-Label Use
Factor VIIa
Hemostatics
Costs and Cost Analysis
Operating Rooms
Cost-Benefit Analysis
Randomized Controlled Trials
Safety
recombinant FVIIa

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Emerging off-label uses for recombinant activated factor VII : Grading the evidence. / Enomoto, T. Miko; Thorborg, Per.

In: Critical Care Clinics, Vol. 21, No. 3 SPEC. ISS., 07.2005, p. 611-632.

Research output: Contribution to journalArticle

Enomoto, T. Miko ; Thorborg, Per. / Emerging off-label uses for recombinant activated factor VII : Grading the evidence. In: Critical Care Clinics. 2005 ; Vol. 21, No. 3 SPEC. ISS. pp. 611-632.
@article{42ead92e595b4d56ab6e41068fea1591,
title = "Emerging off-label uses for recombinant activated factor VII: Grading the evidence",
abstract = "Recombinant factor VIIa holds a great deal of promise as a hemostatic agent in many clinical settings; however, more large, randomized, controlled trials are needed to evaluate both the safety and efficacy of this apparently effective hemostatic agent, particularly in view of its cost. Cost-effectiveness studies are only in the planning stage for rFVIIa as of yet. To become cost-effective, dosing of rFVIIa should avoid costly returns in the operating room, shorten stays in the ICU, and prevent the need to give an additional 10 units of blood.",
author = "Enomoto, {T. Miko} and Per Thorborg",
year = "2005",
month = "7",
doi = "10.1016/j.ccc.2005.04.001",
language = "English (US)",
volume = "21",
pages = "611--632",
journal = "Critical Care Clinics",
issn = "0749-0704",
publisher = "W.B. Saunders Ltd",
number = "3 SPEC. ISS.",

}

TY - JOUR

T1 - Emerging off-label uses for recombinant activated factor VII

T2 - Grading the evidence

AU - Enomoto, T. Miko

AU - Thorborg, Per

PY - 2005/7

Y1 - 2005/7

N2 - Recombinant factor VIIa holds a great deal of promise as a hemostatic agent in many clinical settings; however, more large, randomized, controlled trials are needed to evaluate both the safety and efficacy of this apparently effective hemostatic agent, particularly in view of its cost. Cost-effectiveness studies are only in the planning stage for rFVIIa as of yet. To become cost-effective, dosing of rFVIIa should avoid costly returns in the operating room, shorten stays in the ICU, and prevent the need to give an additional 10 units of blood.

AB - Recombinant factor VIIa holds a great deal of promise as a hemostatic agent in many clinical settings; however, more large, randomized, controlled trials are needed to evaluate both the safety and efficacy of this apparently effective hemostatic agent, particularly in view of its cost. Cost-effectiveness studies are only in the planning stage for rFVIIa as of yet. To become cost-effective, dosing of rFVIIa should avoid costly returns in the operating room, shorten stays in the ICU, and prevent the need to give an additional 10 units of blood.

UR - http://www.scopus.com/inward/record.url?scp=21244463146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244463146&partnerID=8YFLogxK

U2 - 10.1016/j.ccc.2005.04.001

DO - 10.1016/j.ccc.2005.04.001

M3 - Article

C2 - 15992675

AN - SCOPUS:21244463146

VL - 21

SP - 611

EP - 632

JO - Critical Care Clinics

JF - Critical Care Clinics

SN - 0749-0704

IS - 3 SPEC. ISS.

ER -